Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
15. Februar 2022 17:39 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with...
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
07. Februar 2022 18:08 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
27. Januar 2022 16:41 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
19. Dezember 2021 16:47 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a global biopharmaceutical company focused on the development...
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
07. Dezember 2021 17:42 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
30. November 2021 16:45 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and PORTO ALEGRE, Brazil, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory...
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
01. November 2021 19:25 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has...
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
17. August 2021 21:26 ET
|
Telix Pharmaceuticals Limited
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
30. März 2021 18:02 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that it has completed an agreement with...
Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
16. Februar 2021 01:05 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the...